Content deleted Content added
BaeyerDrewson (talk | contribs) |
BaeyerDrewson (talk | contribs) mNo edit summary |
||
| Line 33: | Line 33: | ||
==Related compounds== |
==Related compounds== |
||
The corresponding indole core analogue, '''4F-MDMB-BICA''' or '''4F-MDMB-BUTICA''' has also been sold as a designer drug, first being identified in May 2020.<ref>[https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4F-MDMB-BICA-ID-HIFS-020.pdf Analytical data for 4F-MDMB-BICA. Hungarian Institute for Forensic Sciences. 28-05-2020]</ref> |
The corresponding indole core analogue, '''[[4F-MDMB-BICA]]''' or '''4F-MDMB-BUTICA''' has also been sold as a designer drug, first being identified in May 2020.<ref>[https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/4F-MDMB-BICA-ID-HIFS-020.pdf Analytical data for 4F-MDMB-BICA. Hungarian Institute for Forensic Sciences. 28-05-2020]</ref> |
||
[[Image:4F-MDMB-BICA_structure.png|180px|thumb|left|4F-MDMB-BICA]]{{clear-left}} |
[[Image:4F-MDMB-BICA_structure.png|180px|thumb|left|4F-MDMB-BICA]]{{clear-left}} |
||
Revision as of 01:31, 2 December 2020
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C19H26FN3O3 |
| Molar mass | 363.433 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
4F-MDMB-BINACA (also known as 4F-MDMB-BUTINACA or 4F-ADB) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.[1] It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018. 4F-MDMB-BINACA is an agonist of the CB1 receptor (EC50 = 7.39 nM),[2] though it is unclear whether it is selective for this target.[3] In December 2019, the UNODC announced scheduling recommendations placing 4F-MDMB-BINACA into Schedule II throughout the world.[4]
Related compounds
The corresponding indole core analogue, 4F-MDMB-BICA or 4F-MDMB-BUTICA has also been sold as a designer drug, first being identified in May 2020.[5]
See also
References
- ^ Krotulski, Alex J.; Mohr, Amanda L. A.; Kacinko, Sherri L.; Fogarty, Melissa F.; Shuda, Sarah A.; Diamond, Francis X.; Kinney, William A.; Menendez, M. J.; Logan, Barry K. (September 2019). "4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework". Journal of Forensic Sciences. 64 (5): 1451–1461. doi:10.1111/1556-4029.14101. ISSN 1556-4029. PMID 31260580. S2CID 195770459.
- ^ . doi:10.1021/acschemneuro.0c00644.
{{cite journal}}: Cite journal requires|journal=(help); Missing or empty|title=(help) - ^ "4F-MDMB-BINACA(4F-MDMB-BUTINACA)" (PDF).
- ^ "December 2019 – WHO: World Health Organization recommends 12 NPS for scheduling".
- ^ Analytical data for 4F-MDMB-BICA. Hungarian Institute for Forensic Sciences. 28-05-2020